Aisling Capital — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Marker Therapeutics develops novel T cell therapies, including adoptive T cell therapy approaches, for clinical applications in oncology and other diseases with high unmet need.
BiotechHealthtechHouston, US
Juan Vera(Executive Officer, Director)Dr. Vera(Co-founder)Glynn Wilson(Executive Officer, Director)John Bonfiglio(Executive Officer, Director)
BoardJohn Wilson(Director)
Board seatSteven Elms· per SEC Form D
Co-investorsNew Enterprise Associates (NEA)
BiotechCambridge, US
Dhvanit I Shah(Chief Executive Officer of the Issuer)David Kirske(Executive Officer)Adam Craig(Executive Officer, Director)
BoardGeoff Meyerson(Director)Raymond Kelleher(Director)
Board seatEric Aguiar· per SEC Form D · filed Oct 2024
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.